AIM: To investigate the in vitro release profile of drugs encapsulated within perfluorocarbon (PFC) nanoparticles (NPs) and their ability to inhibit the activity of vascular smooth muscle cells (SMCs). METHODS: Dexamethasone phosphate (DxP) or dexamethasone acetate (DxA) was encapsulated into PFC nanoparticles using a high-pressure homogenous method. The morphology and size of the NPs were examined using scanning electron microscopy (SEM) and a laser particle size analyzer. Drug loading and in vitro release were assessed by high-performance liquid chromatography (HPLC). The impact of NP capsules on SMC proliferation, migration and apoptosis in vitro was assessed using cell counting kit-8, transwell cell migration and flow cytometry assays. RESULTS: The sizes of DxP-NPs and DxA-NPs were 224+/-6 nm and 236+/-9 nm, respectively. The encapsulation efficiency (EE) of DxP-NPs was 66.4%+/-1.0%, with an initial release rate of 77.2%, whereas the EE of DxA-NPs was 95.3%+/-1.3%, with an initial release rate of 23.6%. Both of the NP-coated drugs could be released over 7 d. Human umbilical artery SMCs were harvested and cultured for four to six passages. Compared to free DxP, SMCs treated with tissue factor (TF)-directed DxP-NPs showed significant differences in the inhibition of proliferation, migration and apoptosis (P<0.05). CONCLUSION: The results collectively suggest that PFC nanoparticles will be beneficial for targeted drug delivery because of the sustained drug release and effective inhibition of SMC proliferation and migration.
AIM: To investigate the in vitro release profile of drugs encapsulated within perfluorocarbon (PFC) nanoparticles (NPs) and their ability to inhibit the activity of vascular smooth muscle cells (SMCs). METHODS:Dexamethasone phosphate (DxP) or dexamethasone acetate (DxA) was encapsulated into PFC nanoparticles using a high-pressure homogenous method. The morphology and size of the NPs were examined using scanning electron microscopy (SEM) and a laser particle size analyzer. Drug loading and in vitro release were assessed by high-performance liquid chromatography (HPLC). The impact of NP capsules on SMC proliferation, migration and apoptosis in vitro was assessed using cell counting kit-8, transwell cell migration and flow cytometry assays. RESULTS: The sizes of DxP-NPs and DxA-NPs were 224+/-6 nm and 236+/-9 nm, respectively. The encapsulation efficiency (EE) of DxP-NPs was 66.4%+/-1.0%, with an initial release rate of 77.2%, whereas the EE of DxA-NPs was 95.3%+/-1.3%, with an initial release rate of 23.6%. Both of the NP-coated drugs could be released over 7 d. Human umbilical artery SMCs were harvested and cultured for four to six passages. Compared to free DxP, SMCs treated with tissue factor (TF)-directed DxP-NPs showed significant differences in the inhibition of proliferation, migration and apoptosis (P<0.05). CONCLUSION: The results collectively suggest that PFC nanoparticles will be beneficial for targeted drug delivery because of the sustained drug release and effective inhibition of SMC proliferation and migration.
Authors: H Chaulet; C Desgranges; M A Renault; F Dupuch; G Ezan; F Peiretti; G Loirand; P Pacaud; A P Gadeau Journal: Circ Res Date: 2001-10-26 Impact factor: 17.367
Authors: Gregory M Lanza; Xin Yu; Patrick M Winter; Dana R Abendschein; Kerry K Karukstis; Michael J Scott; Lori K Chinen; Ralph W Fuhrhop; David E Scherrer; Samuel A Wickline Journal: Circulation Date: 2002-11-26 Impact factor: 29.690
Authors: G M Lanza; D R Abendschein; C S Hall; J N Marsh; M J Scott; D E Scherrer; S A Wickline Journal: Invest Radiol Date: 2000-04 Impact factor: 6.016
Authors: Frank D Kolodgie; Michael John; Charanjit Khurana; Andrew Farb; Patricia S Wilson; Eduardo Acampado; Neil Desai; Patrick Soon-Shiong; Renu Virmani Journal: Circulation Date: 2002-09-03 Impact factor: 29.690
Authors: Sun-Joo Lee; Paul H Schlesinger; Samuel A Wickline; Gregory M Lanza; Nathan A Baker Journal: J Phys Chem B Date: 2011-12-06 Impact factor: 2.991